代谢组学技术在心肌梗死生物标志物筛选中的研究进展

Research progress of metabolomics in screening biomarkers of myocardial infarction

心肌梗死是因冠状动脉阻塞导致的心肌缺血性坏死,有较高的发病率和死亡率。代谢功能障碍能反映心肌能量供应和利用的不平衡,且与心血管疾病的发生发展及预后密切相关。目前代谢组学技术已经应用于心肌梗死的研究中,通过对患者体内小分子代谢物的种类、数量及其变化规律进行分析,为心肌梗死的诊断及预后生物标志物筛选提供技术方法和思路。本文将代谢组学技术在心肌梗死生物标志物的相关研究进展进行综述。

Myocardial infarction is the ischemic necrosis of the myocardium caused by coronary artery obstruction,with a high incidence and mortality rate.Metabolic dysfunction can indicate an imbalance in myocardial energy supply and utilization,which is closely related to the occurrence,development,and prognosis of cardiovascular diseases.Currently,metabolomics technology has been applied in the study of myocardial infarction.By analyzing the types,quantities,and patterns of small-molecule metabolites in patients,metabolomics provides technical methods and ideas for the screening of biomarkers of diagnosis and prognostic for myocardial infarction.This article reviews the recent research progress of biomarkers in myocardial infarction using metabolomics technology.